Document:

Sicth Amendment to Distribution Agreement

 Exhibit 10.121 
 SIXTH AMENDMENT TO DISTRIBUTION AGREEMENT 
 This Sixth Amendment to Distribution Agreement
(this “Sixth Amendment”) is dated October 25, 2006 (the “Effective Date” hereof) by and among Argent Development Group, LLC, a California limited liability company (“Argent”), Accentia, Inc., a Florida corporation
(“Accentia”), and TEAMM Pharmaceuticals, Inc., a Florida corporation (“TEAMM”). 
 WHEREAS, Argent, Accentia and
TEAMM entered into a Distribution Agreement dated May 12, 2004 (the “Distribution Agreement”) pertaining, among other things, to a 7.5/200 hydrocodone and ibuprofen Product (the 7.5/200 Product) and a 5.0/200 hydrocodone and ibuprofen
Product (the 5.0/200 Product), as such Distribution Agreement has been amended by the parties from time to time; 
 WHEREAS, Argent,
Accentia and TEAMM have agreed to delete the 7.5/200 Product and the 5.0/200 Product from the Distribution Agreement. 
 NOW,
THEREFORE, pursuant to Section 12.4 of the Distribution Agreement, Argent, Accentia and TEAMM, for good and valuable consideration, including, without limitation, the elimination of the obligation of Accentia and TEAMM to make certain future
payments as set forth in Section 8 of the Distribution Agreement (as amended), and the obligation of Accentia and TEAMM to make a certain payment to Argent as set forth in the Letter Agreement dated October 4, 2006 (and take certain other
actions as set forth therein), as such Letter Agreement has been amended and supplemented by the Letter Agreements dated October 12, 2006, October 23, 2006 and October 24,2006, and for other good and valuable consideration, the
receipt, adequacy and sufficiency of which are hereby acknowledged, do hereby agree as follows: 
 1. Capital terms used herein that
are not otherwise defined shall have the meanings as given to them in the Distribution Agreement (as amended). 
 2. The 7.5/200
Product and the 5.0/200 Product are hereby deleted from the Distribution Agreement (as amended) as of the Effective Date. For the avoidance of doubt, the effect of these deletions is that all rights to “sell” (as that word is defined in
Section 3.1 of the Distribution Agreement) the 7.5/200 Product and the 5.0/200 Product as previously granted by Argent to Accentia and TEAMM in the Distribution Agreement (as amended) are being returned to and vested in Argent, without any
residual rights of any kind remaining with Accentia and TEAMM. 
 3. Except for the Product deletions set forth in Section 2
hereof, the Distribution Agreement (as amended) shall otherwise remain in full force and effect. For the avoidance of doubt, given the Product deletions set forth in Section 2 hereof, and the Product deletions set forth in the Fifth Amendment
to Distribution Agreement being entered into on even date herewith, the only Products remaining in the Distribution Agreement (as amended) are the X/400 Oxy/Acetaminophen Products as defined in the Second Amendment to Distribution Agreement dated
August 15, 2005. The Distribution Agreement remains subject to further amendment by the outstanding Fourth Amendment to Distribution Agreement (previously signed and delivered on behalf of Accentia and TEAMM) which will become effective when
executed and delivered to Accentia and TEAMM by Argent. 

 4. This Sixth Amendment shall be governed and interpreted, and all rights and obligations of the
parties shall be determined, in accordance with the laws of the State of California, without regard to its conflict of laws rules. All disputes with respect to this Sixth Amendment, which cannot be resolved by good faith negotiation among the
parties, shall be brought and heard either in the California State Courts located in Santa Clara County or the United States District Court for the Northern District of California located in San Jose, California. The parties to this Sixth Amendment
each consent to the in personam jurisdiction and venue of such courts. The parties agree that service of process upon them in any such action may be made if delivered in person, by courier service, by facsimile or by certified mail, postage prepaid,
return receipt requested, and shall be deemed effectively given upon confirmed receipt thereof. 
 5. This Sixth Amendment may be
executed in two or three counterparts and any party hereto may execute any such counterpart, all of which when executed and delivered shall be deemed to be an original and to which all counterparts, when fully executed by all of the parties, taken
together shall constitute but one (1) and the same instrument. It shall not be necessary in making proof of this Sixth Amendment or any counterpart hereof to account for any other counterpart except to the extent to show that another party
signed and delivered the counterpart under which it is asserted to have certain responsibilities or obligations. 
 6. This Sixth
Amendment states the entire agreement among the parties hereto with regard to the deletion of the 7.5/200 Product and the 5.0/200 Product from the Distribution Agreement (as amended and amended hereby), and supersedes all and all prior agreements,
commitments, communications, negotiations, offers (whether in writing or oral), representations, statements, understandings and writings pertaining thereto, and may not be amended or modified except by written instrument duly executed and delivered
by all of the parties hereto. 
 IN WITNESS WHEREOF, this Sixth Amendment to Distribution Agreement has been duly executed and
delivered by the parties their duly authorized representatives to be effective as of the Effective Date. 
  

			
	 Argent Development Group, LLC

		
	 By:
	 	 /s/  Kenneth Greathouse

		 	 Kenneth Greathouse

		 	 President

		 	 Date: October 25, 2006

	
	 Accentia Biopharmaceuticals, Inc.

		
	 By:
	 	 /s/  Alan Pearce

		 	 Alan Pearce

		 	 Chief Financial Officer

		 	 Date: October 25, 2006

	
	 TEAMM Pharmaceuticals, Inc.

		
	 By:
	 	 /s/  Nicholas J. Leb

		 	 Nicholas J. Leb

		 	 Vice President, Finance

		 	 Date: October 25, 2006

  

	
	 xc: Hutchison & Mason PLLC

	 3110 Edwards Mill Road, Suite 100

	 Raleigh, North Carolina 27612

	 Attn: J. Robert Taylor, IIITrademark Assignment

 Exhibit 10.122 
 TRADEMARK ASSIGNMENT 
 (NUNC PRO TUNC) 
 Whereas, TEAMM Pharmaceuticals, Inc., a Florida Corporation having a place of business at 2502 Aerial Center Parkway, Morrisville, NC 27560,
(“ASSIGNOR”) has adopted, owned and used the trademark XODOL, registered in the U.S. Patent and Trademark Office, Registration Number 2943009 on April 19, 2005; and 
 Whereas, VICTORY PHARMA, INC., a California Corporation, with its principal place of business at 12707 High Bluff Drive, Suite 200, San Diego,
California 92130, USA, (“ASSIGNEE”) is desirous of acquiring said mark and the registration thereof; 
 Whereas, pursuant to and as
set forth in that certain Asset Purchase Agreement between ASSIGNOR and ASSIGNEE dated October 27, 2006, ASSIGNOR assigns the trademark XODOL, the registration thereof and the goodwill associated therewith to ASSIGNEE; 
 Now, therefore, for good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNOR agrees that ASSIGNOR hereby assigned unto ASSIGNEE
nunc pro tunc effective as of October 27, 2006, all right, title and interest in and to the trademark XODOL throughout the world, the above-identified registration thereof, together with all derivations thereof and including all goodwill
associate therewith, whether based on common law or the laws of the various states, and the right (but not the obligation) to assert such registered trademark and other assigned rights to collect for all past, present and future infringements, and
claims for damages and the proceeds thereof, including, without limitation, license royalties and proceeds of infringement suits and all rights corresponding thereto throughout the world by reason of any past and future acts of infringement that
have occurred or may occur. 
 In testimony Whereof, ASSIGNOR, as represented by one of its of officers, has signed this instrument this
27th day of October 2006. 
  

					
		 	TEAMM Pharmaceuticals, Inc.
			
		 	By:	 	 /s/ Nicholas J. Leb

		 	Name:	 	Nicholas J. Leb

 SWORN to and SUBSCRIBED before me this 27th day of October, 2006. 
  

	
	 /s/ Elizabeth D. Radtke

	Notary PublicTermination of Agreement Letter

 Exhibit 10.123 
 [Mikart, Inc. Letterhead] 
 October 27, 2006 
 TEAMM Pharmaceuticals, Inc. 
 3000 Aerial Center Parkway 
 Suite 110 
 Morrisville, North Carolina 27560 
  

	Attn:	    Martin G. Baum, 

        President and Chief Executive Officer 
  

	 	Re:	Manufacturing and Supply Agreement, dated as of 

	 	    	June 6, 2003 (the “Agreement”), between Mikart, Inc. 

	 	    	(“Mikart”) and TEAMM Pharmaceuticals, Inc. (“TEAMM”) 

 Dear Martin: 
 By executing
this letter below, Mikart and TEAMM hereby terminate the Agreement effective as of the date hereof. Notwithstanding anything in the Agreement to the contrary, neither party shall have any further obligation thereunder to the other, except with
respect to Sections 2.3, 3.2, 3.3(f), 8.1, 10.1 and 13.10 thereof (all of which shall survive the termination of the Agreement). 
 Please
indicate your agreement with the foregoing terms by executing this letter in the space provided below. 
  

			
	Very truly yours,
	
	MIKART, INC.
		
	By:	 	 /s/  Miguel I. Arteche

		 	Miguel I. Arteche, Chairman and
		 	Chief Executive Officer

 Agreed: 
  

			
	TEAMM PHARMACEUTICALS, INC.
		
	By:	 	 /s/  Nicholas J. Leb

		 	Nicholas J. Leb
		 	Vice President, FinanceSettlement of Employment and Compensation Related Matters

 Exhibit 10.125 
 

 
 October 24, 2006 
 Martin G.
Baum 
 6012 Farm Pond Road 
 Apex, NC 27523 
  

	 	Re:	Settlement of Employment and Compensation Related Matters 

 Dear Marty:

 This letter agreement sets forth the terms of a settlement resolving all outstanding issues, compensation, contractual rights and entitlements of any
nature including but not limited to rights to severance and other compensation and all other rights or claims arising from all current and past employment agreements and relationships of Martin G. Baum (“Employee”) with: (i) TEAMM
Pharmaceuticals, Inc. (“TEAMM”), (ii) Accentia Biopharmaceuticals, Inc. (“Accentia”), and (iii) all subsidiaries of Accentia including but without limitation Biovest International, Inc. (“Biovest”)
(collectively “All Accentia Subsidiaries”); Accentia, All Accentia Subsidiaries, and TEAMM are collectively referred to at times herein as the “Entities”. This Letter Agreement is entered into by Employee and Accentia for good
and valuable consideration in hand received and is a binding contract. 
 This Letter Agreement resolves and settles all matters relating to all rights,
claims, actions, obligations, accruals and entitlements of any and all description, including but not limited to all employment, consulting and director relationships, between Employee and each of the Entities (“All Outstanding Rights”) on
an amicable basis, so that both Employee and the Entities can look to the future while maintaining a cordial and professional relationship. 
 In settlement
of any and All Outstanding Rights, of Employee with the Entities, Employee and the Entities agree to the following: 
  

	 	1.	Memorandum of Understanding. On October 12, 2006, Employee and Accentia entered into a Memorandum of Understanding a copy of which is attached as Exhibit A. The
Memorandum of Understanding is superseded by this Letter Agreement. 

 Martin G. Baum 
 October 24, 2006 
 Page 2 
  

	 	2.	Severance. All employment agreements and other relationships including but not limited to director positions held by Employee with each of the Entities, including but without
limitation Accentia, TEAMM and Biovest, and each of their subsidiaries, will be terminated effective on a date after the date hereof to be determined by Accentia but not later than October 28, 2006 (Severance Date). On October 12, 2006,
Employee submitted resignations as a member of the Board of Directors of Accentia, TEAMM and Biovest in the form of Exhibit B which shall survive the execution of this Agreement in Principle and which shall become effective on the last to occur of:
(i) execution of this Letter Agreement and (ii) for each resignation upon the acceptance of the resignation by the Boards of Directors of each of the respective companies. 

  

	 	3.	Severance Compensation. As sole and complete severance compensation, Accentia shall pay Employee: (a) an amount equal to one year of Employee’s current Base Salary
to be paid monthly after all normal withholding and (b) a lump sum severance payment of $30,000 to be paid on the Severance Date (“Severance Compensation”). The Severance Compensation is in full and complete resolution, payment and
settlement of all rights held by Employee related to his employment and all other relationships with each of the Entities, including but without limitation Accentia, TEAMM and Biovest, and each of their subsidiaries from the beginning of time
through the Severance Date including but not limited to the termination of all employment agreements, the satisfaction of any and all severance or compensation obligations, settlement of all accrued compensation, bonus compensation, deferred
compensation, vacation compensation, director compensation or expense reimbursement, expense reimbursement and all other compensation or payment of any nature or description which is owed, claimed or which may in the future be claimed to be owed to
Employee by any of the Entities. Normal FICA and tax withholding will be deducted from the monthly Settlement Compensation and only net amounts will be paid to Employee. Employee shall be responsible for paying his own COBRA payments.

  

	 	4.	Reimbursement. On the Severance Date, without admitting any wrongdoing, Employee shall pay to Accentia $2,760 in settlement of prior disputed expense reimbursements submitted
by Gary Cantrell. 

  

	 	5.	Furniture. Employee may on the Severance Date (in his discretion) purchase the desk and credenza and bookshelf and two file cabinets located in his office for $1,000.

 Martin G. Baum 
 October 24, 2006 
 Page 3 
  

	 	6.	Stock Options. All stock options granted to Employee under the stock option plan of any Entity shall vest on the Severance Date and Employee shall have the time permitted by
the applicable Incentive Stock Option Plan to exercise said options (i.e., 90 days following the Severance Date to exercise options granted under the Accentia Incentive Stock Option Plan and 60 days following the Severance Date to exercise said
options granted under the Biovest Incentive Stock Option Plan). The option shares and other shares in any Entity held by Employee shall not be subject to any company imposed lock-up but all such shares and options of Accentia shall be subject tot
the Accentia Insider Trading Policy for six months following the Severance Date. Employee and Accentia agree that Employee has been granted the following options and except for the following options Employee has no right or claim to any options in
Accentia, Biovest or any other Entity: (i) 336,803 options in Accentia, 100,000 options in Biovest, no options in Teamm and no options in any other Entity or subsidiary of any Entity. 

  

	 	7.	Confidentiality. All existing Confidentiality Agreements and Inventors Rights Agreements between Employee and each Entity shall remain in full effect during the period that
any Severance Compensation is required to be made paid hereunder and shall be enforceable notwithstanding this Letter Agreement or the severance provided for herein. Employee shall treat all information learned during his employment, including but
not limited to information relating to the Entities’ business activities, clinical trials, processes and procedures regarding all products owned or being developed by the Entities including, but not limited to, BiovaxID, AutovaxID, SinuNase,
MDTurbo, AllerNase and all business relationships with any business or governmental entity including the NCI, any clinical site and any investigator regarding each Entity as proprietary and confidential and not disclose same except with the prior
written consent of the Entity. This agreement for Employee to retain all information regarding the Entities confidential shall remain in effect even though the Entities may disclose public information through press releases or filings with the SEC
with the requirement that Employee take a “no comment” position on all information regarding the Entities. Notwithstanding the foregoing, however, nothing herein shall be construed as preventing, restricting, or precluding disclosure of
any information as required by law or pursuant to any subpoena or rule of Court in connection with any litigation, arbitration, governmental investigation, or similar proceeding. 

  

	 	8.	 Non-Competition. The Entities will waive and release Employee from the provisions of any and all existing non-competition agreements provided however, that
for so long as Employee is entitled to receive any Severance Compensation hereunder, Employee shall not solicit any employee of any Entity nor solicit or interfere with the relationship between any Entity and 

 Martin G. Baum 
 October 24, 2006 
 Page 4 
  

	 	 
their customers or any contract parties nor make any negative statement regarding any Entity or the business or business conduct of any Entity.

  

	 	9.	401K. The Employee’s 401(k) account maintained at Morgan Stanley will be disbursed to or for the benefit of Employee in accordance with the provisions of the plan
document. 

  

	 	10.	Recommendations. The termination of Employee will be considered due to strategic considerations and Entities will provide favorable recommendations in the form of Exhibit C
upon request of potential employers. Any public announcement of the severance shall be in the form of Exhibit D provided however Accentia and Biovest may issue a press release and file an 8-K discussing Mr Baum in the same manner as other
non-independent directors resigning from the Board. Accentia and Biovest shall be permitted to make any filings required by the SEC. Employee shall not make any statement that could reasonably be anticipated to damage the reputation or business of
any Entity or any officer or director or affiliate of any Entity. Likewise, the Entities will not disparage Employee in regard to the performance and all other aspects of the Employment relationship with Employee. 

  

	 	11.	General Releases. Upon the Severance Date, Employee and the Entites shall execute and exchange mutual general releases in the form of Exhibit E (in the case of the release to
be executed by Employee) and Exhibit F (in the case of the release to be executed by the Entities). 

  

	 	12.	Choice of law. This Agreement shall be governed by and interpreted in light of the laws of the State of Florida. 

  

	 	13.	Notices. Notices required or permitted to be given pursuant to this Agreement shall be sent via certified RRR or overnight courier, with proof of receipt as follows:

 If to the Entities: 
 Accentia Biopharmaceuticals, Inc. 
 324 S. Hyde Park Avenue, Suite 350 
 Tampa, FL 33606 
 Attn: James A. McNulty,
C.P.A., Secretary/Treasurer 
 If to Employee: 
 Martin G. Baum 
 6012 Farm Pond Road 
 Apex, NC 27523 

 Martin G. Baum 
 October 24, 2006 
 Page 5 
  

	 	14.	Counterparts. This Agreement may be signed in two counterparts, each of which shall constitute an original, but both of which together shall constitute one and the same
agreement. However, this document will not be binding on either of the parties until each party has received delivery of an original executed on behalf of each of the parties. 

 In the event that the terms of settlement outlined in this letter meet with your approval, kindly so indicate by signing where indicated below and returning one signed
copy of this Letter Agreement to my attention. If you should have any questions with regard to this matter, please do not hesitate to contact me. 
 Very
truly yours, 
 Frank E. O’Donnell, M.D. 
 Accentia Biopharmaceuticals, Inc. 
 Teamm Pharmaceuticals, Inc. 
 The undersigned has read and understood the terms set forth
herein and acknowledges, agrees to and accepts these terms. 
  

					
			
	/s/ Martin Baum	 	Date:	 	 10/26/06

	Martin Baum, Individually	 		 	

 Exhibit A 
 MEMORANDUM OF UNDERSTANDING 
 Set forth herein is the understanding of Accentia Biopharmaceuticals, Inc (Accentia)
and Marty Baum (Mr. Baum) regarding the termination of Mr. Baum’s employment and all other relationships with and the satisfaction of all entitlements of Mr. Baum including but not limited to compensation, bonuses, severance payments,
vacation and all other entitlements of any description from Accentia and each of its subsidiaries including but not limited to Biovest International, Inc. (Subsidiaries). This Memorandum of Understanding is subject to the approval of the Board of
Directors of Accentia and is further subject to the execution of a mutually agreeable definitive Severance Agreement by Accentia and Mr. Baum. 
  

	 	1.	Severance. All employment agreements and other relationships including but not limited to director positions with Accentia and each of its Subsidiaries will be terminated effective
on a date after the date hereof to be determined by Accentia but not later than October 28, 2006 (Severance Date). On the date hereof, Mr. Baum shall tender his resignation from the Board of Directors of Accentia, Teamm and Biovest subject
to the condition that the Accentia Board of Directors approves this Memorandum of Understanding. 

  

	 	2.	Severance Compensation. As sole and complete severance compensation, Accentia shall pay Mr. Baum: (a) an amount equal to one year of Mr. Baum’s current Base
Salary to be paid monthly after all normal withholding and (b) a lump sum severance payment of $30,000 to be paid on the Severance Date. 

  

	 	3.	Reimbursement. On the Severance Date, without admitting any wrong doing, Mr. Baum shall pay Accentia $2,760 in settlement of prior disputed expense reimbursements submitted by
Gary Cantrell. 

  

	 	4.	Furniture. Mr. Baum may on the Severance Date (in his discretion) purchase the desk and credenza and bookshelf and two file cabinents located in his office for $1,000.

  

	 	5.	Stock Options. All stock options granted to Mr. Baum under the Accentia and Subsidiary stock option plan shall vest on the Severance Date and Mr. Baum shall have 90 days
following the Severance Date to exercise said options. The option shares and other shares held by Mr. Baum shall not be subject to any company imposed lock-up but all such shares shall be subject tot the Accentia Insider Trading Policy for six
months following the Severance Date. 

  

	 	6.	General Releases. On the Severance Date, the parties shall exchange mutual general releases. 

	 	7.	Covenant Not to Compete. Mr. Baum’s existing Covenant Not to Compete shall be terminated on the Severance Date and Mr. Baum shall then be relieved of any obligation
thereunder. However, Mr. Baum shall remain subject to existing restrictions on solicitation of employees, customers or contract parties of Accentia and its Subsidiaries. 

  

	 	8.	References. The parties shall agree to make no disparaging statements regarding each other and Accentia shall agree to provide favorable recommendations for Mr. Baum. Any
announcement of the severance shall be in the Accentia press release regarding the re-alignment of the Board of Directors to achieve independence as required by NASDAQ. 

  

							
	Accentia Biopharmaceuticals, Inc.	 		 		 	
				
	   	 		 	Dated:	 	______________________
	Sam Duffey, General Counsel	 		 		 	
				
	   	 		 	Dated:	 	______________________
	Marty Baum	 		 		 	

 Exhibit B 
 [TEAMM Letterhead] 
 Board of Directors 
 Teamm Pharmaceuticals, Inc. 
 Attention: Frank O’Donnell
                                        
                            October 26, 2006 
 Gentlemen, 
 I hereby tender my resignation
from the Board of Directors of Teamm Pharmaceuticals, Inc (“Teamm”) and from membership on all committees of the Teamm Board of Directors to be effective upon acceptance by the Teamm Board of Directors. I have enjoyed the opportunity to
serve with you on Teamm’s Board and wish you and Teamm great success. 
  

	
	Sincerely,
	
	/s/ Marty Baum
	Marty Baum

 Board of Directors 
 Accentia
Biopharmaceuticals, Inc. 
 Attention: Frank O’Donnell, Chairman
                                        
            October 26, 2006 
 Gentlemen, 
 I hereby tender my resignation from the Board of Directors of Accentia Biopharmaceuticals, Inc (“Accentia”) and from membership on all
committees of the Accentia Board of Directors to be effective upon acceptance by the Accentia Board of Directors. I have enjoyed the opportunity to serve with you on Accentia’s Board and wish you and Accentia great success. 
  

	
	Sincerely,
	
	/s/ Marty Baum
	Marty Baum

 Board of Directors 
 Biovest
International, Inc. 
 Attention: Steve Arikian
                                        
                            October 26, 2006 
 Gentlemen, 
 I hereby tender my resignation
from the Board of Directors of Biovest International, Inc. (“Biovest”) and from membership on all committees of the Biovest Board of Directors to be effective upon acceptance by the Biovest Board of Directors. I have enjoyed the
opportunity to serve with you on Biovest’s Board and wish you and Accentia great success. 
  

	
	Sincerely,
	
	/s/ Marty Baum
	Marty Baum

 Exhibit E 
 RELEASE OF ALL CLAIMS 
 The undersigned Martin Baum ( “Releasor”) in connection with a
settlement agreement resolving all employment-related claims by and with regard to the Releasees (as defined below) hereby releases and forever discharges Accentia Biopharmaceuticals, Inc. (“Accentia”), TEAMM Pharmaceuticals, Inc.
(“TEAMM”), Biovest International, Inc., (“BioVest”) and Analytica International, Inc., as well as all officers and directors of each of the foregoing corporations and their subsidiaries, affiliates, agents, servants, employees,
officers, insurers, successors, and assigns, and each and every one of them (hereinafter collectively referred to as “Releasees”) of and from any and all claims, demands or causes of action, which the Releasor now has or claims to have, or
which may hereinafter accrue against the Releasees, arising or growing out of any event occurring at any time before the date hereof, including, without limiting the generality of the foregoing, all claims, demands or causes of action arising out of
employment agreements and transactions involving Releasor and any one or more of the Releasees. Nothing herein shall be construed to release or otherwise effect any obligation of Releasor to repay money borrowed by Releasor from
Dr. O’Donnell or any affiliate of Dr. O’Donnell. 
 The undersigned agrees to defend, protect, indemnify and save harmless the said
Releasees if any person, firm or corporation shall assert or attempt to assert any claim hereby released in settlement. 
 The amounts paid by
or on behalf of said Releasees was paid in strict settlement and compromise of the claim, without in any way admitting liability by or on behalf of the Releasees, or to be considered or construed as a waiver by, an estoppel against, or a bar to any
Releasee denying liability in other proceedings. No promise has been made to pay any further or other sums or any other further or other consideration for this Release. This is a full and final release for all liability and/or damage known and
unknown. 
 The undersigned is of legal age, under no disability and is duly authorized to execute the Release, and has read and fully understands
the above and foregoing Release. The terms of this Release are contractual and not a mere recital. 
 Wherever in this instrument any party
shall be designated or referred to by name or general reference, such designation is intended to and shall have the same effect as if the words “heirs, executors, administrators, personal or legal representatives, successors and assigns”
had been inserted after each and every such designation and all the terms, easements and conditions herein contained shall be for and shall inure to the benefit of and shall bind the respective parties hereto, and their heirs, executors,
administrators, personal or legal representatives, successors and assigns, respectively. 

 IN WITNESS WHEREOF, the said Releasor has hereunto set his hand and seal or caused these presents to be signed by their
proper corporate officers and its corporate seal to be hereto affixed, this 26th day of October 2006. 
  

			
	 Signed, Sealed and Delivered
 in the presence
of
 or attested
	 	
		
	 /s/ Martin Baum
	 	(L.S.)
		 	

 State of North Carolina, County of Wake: 
 Be it Remembered, that on October 26, 2006, before me the subscriber, a Notary/ Attorney-at-law of             , personally appeared Martin Baum and
             who, I am satisfied are the person(s) named to and who executed the within Instrument, and thereupon they acknowledged that they signed, sealed and delivered the same as their
act and deed, for the uses and purposes therein expressed. 
  

	
	
	 /s/ Elizabeth D. Radtke

	Notary/Attorney-at-law of

 Exhibit F 
 RELEASE OF ALL CLAIMS 
 The undersigned Accentia Biopharmaceuticals, Inc. , TEAMM Pharmaceuticals, Inc.,
Biovest International, Inc., and Analytica International, Inc. (collectively referred to as “Releasors”), in connection with a settlement agreement resolving all employment-related claims by and with regard to Martin Baum
(“Releasee”), and in consideration thereof, each of the undersigned hereby releases and forever discharges said Releasee, his agents, servants, employees, officers, insurers, successors, and assigns, and each and every one of them, of and
from any and all claims, demands or causes of action, which the undersigned now has or claims to have, or which may hereinafter accrue against the Releasee, arising or growing out of any event occurring at any time before the date hereof, including,
without limiting the generality of the foregoing, all claims, demands or causes of action arising out of employment agreements and transactions involving any one of more of the Releasors and Releasee. Nothing herein shall be construed to release or
otherwise effect any obligation of Releasee to repay money borrowed by Releasee from Dr. O’Donnell or any affiliate of Dr. O’Donnell. 
 The undersigned agrees to defend, protect, indemnify and save harmless the said Releasee if any person, firm or corporation shall assert or attempt to assert any claim hereby released in settlement. 
 The covenants and agreements entered into on behalf of said Releasee were made in strict settlement and compromise of any and all existing or potential
claims, without in any way admitting liability by or on behalf of the Releasee, or to be considered or construed as a waiver by, an estoppel against, or a bar to the Releasee denying liability in other proceedings. No promise has been made to pay
any further or other sums or any other further or other consideration for this Release. This is a full and final release for all liability and/or damage known and unknown. 
 The undersigned are each corporate entities in good standing and are authorized to enter into this Release, and have read and fully understand the above and foregoing Release. The terms of this Release are contractual
and not a mere recital. 
 Wherever in this instrument any party shall be designated or referred to by name or general reference, such
designation is intended to and shall have the same effect as if the words “heirs, executors, administrators, personal or legal representatives, successors and assigns” had been inserted after each and every such designation and all the
terms, easements and conditions herein contained shall be for and shall inure to the benefit of and shall bind the respective parties hereto, and their heirs, executors, administrators, personal or legal representatives, successors and assigns,
respectively. 

 IN WITNESS WHEREOF, each of the said Releasors has hereunto set its hand and seal or caused these presents to be signed
by its proper corporate officers and its corporate seal to be hereto affixed, this     day of         2006. 
  

									
	 Signed, Sealed and Delivered
 in the presence of
 or attested
	 		 		 		 	
					
	 Accentia Biopharmaceuticals, Inc.
	 		 		 	Biovest International, Inc.	 	
					
	 /s/ Francis E. O’Donnell, Jr.
	 	 (L.S.)
	 	   	 	 /s/ Steven Arikian
	 	(L.S.)
					
	 Analytica International, Inc.
	 		 		 	TEAMM Pharmaceuticals, Inc.	 	
					
	 /s/ Steven Arikian
	 	 (L.S.)
	 	   	 	 /s/ Francis E. O’Donnell, Jr.
	 	(L.S.)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00115-of-00352.parquet"}]]